Loading provider…
Loading provider…
Pediatric Pulmonology Physician in Boston, MA
NPI: 1104180579Primary Practice Location
BOSTON CHILDREN'S HOSPITAL
300 Longwood Ave, Boston, MA
Primary Employer
Children's Hospital Pediatric Associates, Inc
childrenshospital.org
HQ Phone
Get M.D. Ryan's Phone Numberphone_androidMobile
Get M.D. Ryan's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMA State Medical License
MA State Medical License
2017 - 2026
MS State Medical License
2016 - 2017

American Board of Internal Medicine
Internal Medicine

American Board of Pediatrics
Pediatric Pulmonology

American Board of Pediatrics
Pediatrics

American Board of Internal Medicine
Pulmonary Disease
LSU Health Shreveport School of Medicine
schoolofmedicine.lsuhs.edu
Medical School
Until 2012
Harvard School of Public Health
MPH • Clinical Effectiveness
2022 - 2024
Boston Children’s Hospital
Fellowship • Harvard-Wide Pediatric Health Services Research Fellowship
2022 - 2024
Brigham and Women’s Hospital
Fellowship • Adult Pulmonary Medicine
2019 - 2021
Boston Children’s Hospital/Boston Medical Center
Fellowship • Pediatric Pulmonology
2017 - 2021
University of Mississippi Medical Center
umc.edu
Internship • Internal Medicine/Pediatrics
2012 - 2013
Chief Residency • Internal Medicine
2016 - 2017
Residency • Internal Medicine/Pediatrics
2014 - 2016
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 11 | 26 |
Antifibrinolytic Agents for Hemoptysis Management in Adults With Cystic Fibrosis.
Lead Sponsor: Clarametyx Biosciences, Inc.
Intervention / Treatment: DRUG: Placebo, DRUG: CMTX-101
Lead Sponsor: ReCode Therapeutics
Intervention / Treatment: OTHER: Placebo, DRUG: RCT2100
Lead Sponsor: Anagram Therapeutics, Inc.
Intervention / Treatment: DRUG: ANG003